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Routinely available cotrimoxazole prophylaxis and
occurrence of respiratory and diarrhoeal morbidity in
infants born to HIV-infected mothers in South Africa
Anna Coutsoudis, Kubendran Pillay, Elizabeth Spooner, Hoosen M Coovadia, Lucy Pembrey, Marie-Louise Newell
Objectives. To examine the influence of cotrimoxazole (CTM)
prophylaxis on incidence of lower respiratory tract infections
(LRTIs) and diarrhoea.
Design.  A prospective observational cohort study.  Morbidity
and feeding data on infants born to HIV-infected mothers
were collected routinely at clinic visits at 1 week, 6 weeks and
3 months, and 3-monthly thereafter, with blood drawn for
determining HIV status. 
Setting. Two hospitals in Durban, South Africa.  In one
hospital (King Edward VIII Hospital), infants born to HIV-
infected mothers recieved CTM prophylaxis and in the other
(McCord Hospital) infants did not receive CTM prophylaxis.  
Subjects. Infants born to HIV-infected mothers.
Outcome measures.  Incidence of LRTI and diarrhoea.
Results. In multivariate analysis controlling for breast-feeding
status, number of clinic visits and HIV infection status, HIV-
infected infants with access to CTM prophylaxis had a
significantly lower incidence of LRTI (82%) than those
without access to prophylaxis.  However in HIV-uninfected
infants, this was not the case. CTM prophylaxis was
associated with a non-significant increased risk for diarrhoea
in both infected (odds ratio (OR) 1.58, p = 0.45) and unin-
fected infants (OR 1.52, p = 0.10).  
Conclusions. This observational study confirms current
thinking that CTM prophylaxis is protective against LRTIs in
HIV-infected children.  However, because of a possible
association between CTM prophylaxis and an increased risk
of diarrhoea, HIV status of infants should be determined as
early as possible in order to prevent unnecessary exposure of
uninfected infants to CTM prophylaxis, while further studies
to quantify both beneficial and adverse effects of CTM
prophylaxis are undertaken.
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Cotrimoxazole (CTM) is recommended as standard-of-care for
prophylaxis against Pneumocystis carinii pneumonia (PCP) in all
infants born to HIV-infected mothers in industrialised
countries.1 Primary prophylaxis with CTM is effective in
decreasing the frequency of PCP and early death in infants
with perinatal HIV infection.2 The high morbidity and
mortality of HIV-infected infants in developing countries,3 and
the demonstration that much of this is due to P. carinii4-7 and
acute bacterial infections,8 has led to increasing support for the
incorporation of CTM into prevention and care programmes
for infected children.9 However, to date the effectiveness of
CTM prophylaxis in HIV-infected infants and children has not
been proved in randomised controlled trials. The drug is not
routinely employed for prophylaxis against infections in Africa,
as clinicians and policy makers remain sceptical of any
putative benefit and wary of adding unjustifiable costs. Four
issues, which are of particular relevance to resource-
constrained environments, provide an incentive for more data.
Firstly, the recent global expansion of programmes for the
prevention of mother-to-child transmission (PMTCT) of HIV
has led to increased rates of diagnosis of HIV-infected and
HIV-exposed infants, especially in developing countries.
Fifteen African countries have instituted PMTCT programmes
and it is estimated that about 250 000 pregnant African women
will have access to voluntary counselling and testing (VCT)
within 2 years.3 Secondly, adherence to frequent use of the
drug can be anticipated to be sub-optimal.  The common
practice in many African countries of recommending CTM for
all HIV-exposed infants (because of the expense of diagnosing
HIV at this age) means that the number of infants subjected to
CTM will increase. This will compound the substantial
problem of bacterial resistance to CTM in many African
countries and render a useful and affordable drug
ineffective.10,11 Thirdly, there is real concern that treating the
large number of HIV-uninfected infants will increase service
delivery burdens of already fragile systems. Adverse effects of
CTM have been reported, ranging from skin reactions and
gastrointestinal disturbances to blood dyscrasias, and from
mild to lethal.12 Lastly, there are no reliable data on outcomes of
CTM prophylaxis in children in developing countries, although
some information has been obtained from observational studies
in Thailand13 which showed that CTM reduced the risk of
pneumonia in HIV-infected children.  Moreover, it is not
known whether CTM exerts any benefit in breast-fed HIV-
infected infants. Breast-feeding is known to be protective,
reducing lower respiratory tract infections (LRTIs) and
diarrhoea in particular, and this effect is especially pronounced
in the first 6 months of life.14 Therefore CTM prophylaxis may
either not add any further benefit or its prophylactic effects
may become undetectable.  
A randomised controlled trial of CTM prophylaxis in HIV-
exposed infants is currently being conducted in Zambia and
Tanzania but results are not expected for some time because of
the large numbers of HIV-infected children needed. However,
in the absence of trial results our observational data provide an
opportunity to inform the debate and to assess the benefit of
routine provision of CTM prophylaxis to all infants born to
HIV-infected women. We have data collected within a
previously reported vitamin A intervention trial15 conducted in
two clinics in Durban; in one clinic CTM was routinely
provided to all children born to HIV-infected women and in
the other it was not. In all other respects the enrolled infants
were treated similarly, according to protocol requirements. In
the first clinic the clinician in charge (KP) followed
international guidelines, i.e. prophylaxis was provided for all
HIV-exposed infants, and in the second the clinician in charge
(ES) followed the South African guidelines at that time (1995 -
1998) which did not advocate routine prophylaxis.  We
investigated whether provision of routine CTM prophylaxis
reduced the risk of LRTI and/or diarrhoea episodes in children
of HIV-infected mothers and analysed the data according to
infant feeding patterns.
Methods
Details of the study population and data collection have been
described previously.15 Briefly, the mother/infant pairs in the
study were participating in a vitamin A intervention trial to
reduce MTCT of HIV-1.  The study was conducted at antenatal
clinics at 2 hospitals in Durban: King Edward VIII Hospital
(KEH) and McCord Hospital (MH).  Women were recruited
between July 1995 and April 1998 and were randomised to
vitamin A or placebo. No women in the study received any
antiretroviral therapy, which was not available at the time the
study was conducted. The study was approved by the Ethics
Committee of the University of Natal.  Written informed
consent was obtained from all women who participated in the
trial.
Mothers were asked to attend a follow-up clinic when their
infants were 1 week, 6 weeks and 3 months of age, and
thereafter every 3 months.  At each paediatric follow-up visit
mothers were asked about breast-feeding and other infant
feeding practices; infants were examined by a clinician and
morbidity was recorded according to the study protocol.  In
addition, history of morbidity since the last visit was collected
and anthropometric measurements were taken at each visit.
Diarrhoea was defined as 4 or more watery, loose stools per
day and LRTI was defined as cough and tachypnoea.
Infant venous blood was drawn on the first day after birth
and again at 1 week, 6 weeks and 3 months of age, and 3-
monthly thereafter until 15 months of age. If children were
breast-fed beyond 15 months an additional sample was drawn
at least 6 weeks after complete cessation of breast-feeding.
Plasma samples collected from children before 9 months of age
were tested using a quantitative assay of HIV viral RNA using
polymerase chain reaction (PCR, Roche Molecular Systems,
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Branchburg, New Jersey, USA). A sample with more than 400
HIV viral copies per millilitre was designated as a positive test.
Samples collected from children after 9 months of age were
tested for HIV antibodies (Abbott Laboratories, Chicago).
Children were diagnosed as HIV-infected if they had 2 or more
positive PCRs and/or were antibody-positive at 15 months of
age.  They were confirmed HIV-uninfected if they had never
had a positive PCR and had at least 1 negative PCR 1 month
after cessation of breast-feeding, or if they were antibody-
negative 6 weeks after cessation of breast-feeding. Two children
were presumed to be uninfected because they had at least 1
negative PCR, no positive PCRs and at least 1 negative
enzyme-linked immunosorbent assay (ELISA), but the last
negative ELISA was less than 6 weeks after cessation of breast-
feeding. 
Statistical analyses 
Analyses were performed using Stata 7.0 (Stata Corporation,
Texas, USA). Odds ratios (ORs) and 95% confidence intervals
(CIs) were calculated and logistical regression was used to
adjust for potential confounding factors. Breast-feeding status
was categorised as ‘ever’ or ‘never’. Breast-feeding, HIV
infection status and clinic (provision of CTM or not) were
included in the models as these factors were considered to be
associated with morbidity a priori. The number of visits was
also included to allow for the fact that children who attended
the clinic less frequently were less likely to be diagnosed as
having illnesses.
Results
Women participating in this study had been randomly
assigned to receive vitamin A or placebo during the last
trimester of pregnancy. As there was no effect of vitamin A
supplementation on the risk of MTCT of HIV-1 infection,15 the
two treatment groups were combined for analysis. Furthermore
it is unlikely that vitamin A supplementation given to the
mother during the last trimester of pregnancy would have any
impact on long-term morbidity of infants.  Information was
available on a total of 738 mother/child pairs (second twins
excluded). Of these, 15 mothers defaulted before delivery and 6
at delivery (20 were recruited at MH and 1 at KEH). Forty-nine
children died during follow-up at a median age of 3 months
(range 0 - 20 months); 305 children were lost to follow-up, 70%
(N = 213) before 3 months of age; leaving 363 children with
complete and prolonged follow-up (completers).  The
proportion of completers and non-completers was similar at
each of the two clinic sites, suggesting equal access to CTM
prophylaxis.  There were no major differences in socio-
demographic characteristics of completers and non-completers.
Neither were there any differences in socio-demographic
characteristics between the mothers enrolled in the 2 different
hospitals.
Of the 363 children with complete follow-up information,
181 were male and 182 were female. Two-thirds (N = 238) were
breast-fed and one-third (N = 125) were known to have never
been breast-fed. Sixty-two children (17%) were HIV-infected,
299 (82%) were uninfected and 2 (0.5%) were presumed to be
uninfected. One hundred and fifty-four children were seen at
KEH and 209 at MH.
Most children (N = 334, 92%) had information available from
5 or 6 follow-up visits (range 2 - 6 visits). One-third of children
(N = 118) had no illness episodes at all during follow-up and
another third (N = 122) had 2 or more episodes of illness. 
Mortality
Of the 49 children who died, 19 died at KEH and 30 at MH.
HIV infection status was determined for 39 children and cause
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Table I. Univariate and multivariate analyses — risk factors for ever having an illness episode
Odds ratio
No. of children adjusted for all 
Ever ill Never ill Unadjusted odds other variables
(N = 245) (N = 118) ratio (95% CI) p-value (95% CI) p-value
Breast-fed (%)
Ever 157 (66.0) 81 0.81 (0.51 - 1.30) 0.39 0.84 (0.51 - 1.38) 0.49
Never 88 (70.4) 37
HIV status (%)  
Infected 55 (88.7) 7 4.59 (2.02 - 10.43) < 0.001 4.56 (1.98 - 10.49) < 0.001
Uninfected 190 (63.1) 111
CTM (%)
Provided 93 (60.4) 61 0.57 (0.37 - 0.89) 0.01 0.66 (0.41 - 1.05) 0.08
Not provided 152 (72.7) 57
No. of visits (%)
2 - 4 13 (44.8) 16 0.36 (0.17 - 0.77) 0.009 0.38 (0.17 - 0.85) 0.02
5 or 6 232 (69.5) 102
CTM = cotrimoxazole.
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of death was known for 44 of 49.  Among 29 HIV-infected
infants with known cause of death, pneumonia was the sole or
contributing cause of death in 6 of 13 children (46%) at KEH
where CTM is routinely provided compared with 11 of 16
children (69%) at MH where CTM was not provided; however
this difference was not statistically significant. There were no
pneumonia-related deaths among HIV-uninfected infants at
either clinic. Grouping sepsis and septicaemia with pneumonia,
7 of 13 deaths (54%) among HIV-infected infants at KEH were
due to these causes compared with 11 of 16 deaths (69%)
among HIV-infected infants at MH (not a statistically
significant difference). Serious bacterial infection was the cause
of the only death at KEH in an uninfected child, and the cause
of 2 of 5 deaths among uninfected infants at MH.
Overall morbidity
A total of 245 of 363 children had at least 1 illness episode, with
HIV-infected children being significantly more likely to have
had any morbidity than uninfected children (adjusted OR 4.56,
p < 0.001).  Table I shows the effect of breast-feeding, HIV
infection status, access to CTM and number of visits on the risk
of ever having an illness episode, both in univariate and
multivariate analyses.  
In univariate analysis, children with access to CTM were
significantly less likely to have ever had an illness episode than
children seen where CTM prophylaxis was not routinely
provided, but the OR increased slightly and was of borderline
significance when HIV infection status, breast-feeding and
number of visits were taken into account (Table I).
Given the dominant effect of HIV infection status on
morbidity, we also analysed morbidity in the 2 infection groups
separately. Among the 62 HIV-infected children, 80% (16/20) of
those with access to CTM were ever ill compared with 93%
(39/42) of those who did not have access to CTM (unadjusted
OR = 0.31, 95% CI: 0.06 - 1.60, p = 0.14). The apparently
protective effect of CTM was not statistically significant owing
to the small numbers (N = 7) of infected children who were
never ill. A borderline significant association in the same
direction was seen among uninfected children — 57% (77/135)
of those with access to CTM were ever ill compared with 68%
(113/166) of those who did not (unadjusted OR = 0.65, 95% CI:
0.40 - 1.04, p = 0.07). HIV infection was associated with breast-
feeding (x2 = 3.47, p = 0.06), but never breast-feeding did not
significantly increase the likelihood of being ill among either
the HIV-infected or the uninfected children.
As the effect of CTM prophylaxis may vary by type of
morbidity, we also analysed the data for LRTI (68 children with
at least 1 episode) and diarrhoea (113 children with at least 1
episode) separately.
LRTI
The results of univariate and multivariate analyses of the risk
of ever having a LRTI are presented in Table II. Children
provided with CTM were significantly less likely to have ever
had a LRTI episode than children without access to CTM, even
when adjusting for breast-feeding, HIV infection status and
number of visits (adjusted OR = 0.41, p = 0.005). As expected,
infected children were significantly more likely to ever have an
LRTI episode than uninfected children (adjusted OR 3.01, p =
0.001). There was no significant difference in risk of LRTI by
breast-feeding status (Table II).
CTM was apparently associated with a protective effect
against LRTI among both HIV-infected and uninfected
children, with the strongest effect observed for the infected
children. Among the HIV-infected children, only 15% (3/20) of
those who were provided with CTM had a LRTI compared
with 45% (19/42) of those who were not (OR 0.21, 95% CI: 0.05
- 0.91, p = 0.02). Similarly, 10% (13/130) of the uninfected
children with access to CTM had a LRTI compared with 20%
342
Table II. Univariate and multivariate analyses – risk factors for ever having a LRTI
No. of children Odds ratio 
Ever had Never had adjusted for all
a LRTI a LRTI Odds other variables,
(N = 68) (N = 295) ratio (95% CI) p-value (95% CI) p-value
Breast-fed (%)
Ever 39 (16.4) 199 0.65 (0.38 - 1.11) 0.12 0.68 (0.38 - 1.21) 0.19
Never 29 (23.2) 96
HIV status (%)
Infected 22 (35.5) 40 3.05 (1.66 - 5.60) < 0.001 3.01 (1.60 - 5.67) < 0.001
Uninfected 46 (15.3) 255
CTM (%)
Provided 16 (10.4) 138 0.35 (0.19 - 0.64) < 0.001 0.41 (0.22 - 0.77) 0.05
Not provided 52 (24.9) 157
No. of visits (%)
2 - 4 3 (10.3) 26 0.48 (0.14 - 1.63) 0.24 0.61 (0.17 - 2.14) 0.44
5 or 6 65(19.5) 269
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(33/165) of those without (OR 0.44, 95% CI: 0.22 - 0.87, p =
0.02).
Breast-feeding is a route of transmission of HIV infection and
is also known to be associated with decreased risk of LRTI,
especially early in life, and it was therefore important to
examine the relationship between these factors more closely for
possible interactions. The effect of breast-feeding on risk of
LRTI was shown to depend on HIV infection status. Among
uninfected children breast-feeding was associated with a
significantly reduced risk of LRTI: 11% (21/191) of uninfected
breast-fed children had a LRTI compared with 23% (25/110) of
children who had never been breast-fed (OR 0.42, 95% CI: 0.22
- 0.80, p = 0.007). In the HIV-infected group, 38% (18/47) of
those who were breast-fed had a LRTI compared with 27%
(4/15) of those who were never breast-fed (OR 1.71, 95% CI:
0.46 - 6.29, p = 0.42).
Diarrhoea
Table III shows the results of analyses relating to the risk of
ever having an episode of diarrhoea. In univariate and
multivariate analyses breast-feeding, HIV infection status and
number of visits were not associated with ever having had a
diarrhoea episode. However, children seen where CTM is
routinely provided were more likely to have ever had an
episode of diarrhoea than children not receiving CTM although
this association was only of borderline significance in both
univariate and multivariate analyses (adjusted OR 1.55, p =
0.07).
Among HIV-infected children, 40% (8/20) of those with
access to CTM had diarrhoea compared with 31% (13/42) of
those who did not receive CTM (OR 1.49, 95% CI: 0.48 - 4.57, 
p = 0.49). Among the uninfected children, 36% (48/132) of
those receiving CTM had diarrhoea compared with 26%
343
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Table III. Univariate and multivariate analyses — risk factors for ever having an episode of diarrhoea
No. of children Odds ratio 
Ever had Never had adjusted for all
diarrhoea diarrhoea Odds other variables
(N = 113) (N = 250) ratio (95% CI) p-value (95% CI) p-value
Breast-fed (%)
Ever 75 (31.5) 163 1.05 (0.66 - 1.68) 0.83 0.948 (0.58 - 1.52) 0.79
Never 38 (30.4) 87
HIV status (%)
Infected 21 (35.6) 41 1.16 (0.65 - 2.08) 0.61 1.25 (0.69 - 2.25) 0.47
Uninfected 92 (30.8) 209
CTM (%)
Provided 56 (36.4) 98 1.52 (0.97 - 2.38) 0.07 1.55 (0.97 - 2.46) 0.07
Not provided 57 (27.3) 152
No. of visits (%)
2 - 4 11 (37.9) 18 1.39 (0.63 - 3.05) 0.41 1.31 (0.59 - 2.90) 0.51
5 or 6 102(30.5) 232
Table IV. Multivariate analyses stratified by HIV infection status
HIV-infected children (N = 62) Uninfected children (N = 301)
OR adjusted for OR adjusted for
other variables other variables
(95% CI) p-value (95% CI) p-value
Ever ill
Breast-fed* 1.71 (0.25 - 11.59) 0.58 0.79 (0.47 - 1.32) 0.37
CTM† 0.38 (0.06 - 2.28) 0.29 0.70 (0.43 - 0.13) 0.14
No. of visits‡ 0.13 (0.01 - 1.25) 0.08 0.46 (0.20 - 1.05) 0.06
LRTI
Breast-fed* 2.31 (0.59 - 8.98) 0.23 0.49 (0.26 - 0.95) 0.03
CTM† 0.18 (0.04 - 0.77) 0.02 0.52 (0.26 - 1.05) 0.07
No. of visits‡ 1.41 (0.12 - 17.08) 0.79 0.56 (0.13 - 2.50) 0.45
Diarrhoea
Breast-fed* 0.44 (0.13 - 1.51) 0.19 1.08 (0.63 - 1.83) 0.79
CTM† 1.58 (0.49 - 5.16) 0.45 1.52 (0.92 - 2.53) 0.10
No. of visits‡ 1.69 (0.21 - 13.89) 0.63 1.23 (0.52 - 2.92) 0.64
*Ever v. never (never as the reference category).
†Provided v. not provided (not provided as the reference category).
‡ 2 - 4 visits v. 5 or 6 visits (5 or 6 visits as the reference category).
CTM = cotrimoxazole.
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(44/169) of those who did not receive CTM (OR 1.56, 95% CI:
0.95 - 2.56, p = 0.08).
Thirty per cent (14/47) of the infected children who were
breast-fed had diarrhoea compared with 47% (7/15) of those
who were never breast-fed (OR 0.48, 95% CI: 0.14 - 1.63, p =
0.23). Among the uninfected children 32% (61/191) of those
who were breast-fed had diarrhoea and 28% (31/110) of those
who were never breast-fed had diarrhoea (OR 1.20, 95% CI:
0.71 - 2.00, p = 0.50).
Morbidity, LRTI and diarrhoea in infected and
uninfected children
Because of the complex nature of the relationships between
HIV infection, breast-feeding and morbidity, multivariate
analyses were also performed separately for HIV-infected and
uninfected children (Table IV). The protective effect of CTM
against LRTI was strongest among HIV-infected children and
only of borderline significance in the uninfected group.
Although breast-feeding was not significantly associated with a
reduced risk of LRTI overall, a significant protective effect was
observed among the uninfected children. 
Possible difference between the two clinics
The provision of CTM was clinic based and an assessment of
the effect of CTM must therefore take into account other
factors, which may have differed between the clinics. CTM was
provided routinely at KEH but not at MH. Interaction between
breast-feeding (ever/never) and clinic was investigated by
adding an interaction term to the full multivariate models but
none of the likelihood ratio test results were significant (all
morbidity x2(1) = 0.15, p = 0.70; LRTI x2(1) = 1.42, p = 0.23;
diarrhoea x2(1) = 0.63, p = 0.43). 
Discussion
Children seen in clinics with routine provision of CTM
prophylaxis and who were subsequently shown to be HIV-
infected had a significantly lower incidence of LRTI than
children without access to prophylaxis.  However, in infants
who were HIV-uninfected, the lower incidence of LRTI
associated with CTM prophylaxis was not significant.  CTM
prophylaxis in children was associated with a non-significant
increased risk for diarrhoea in both infected and uninfected
children.
These findings have important implications as they confirm
that providing HIV-infected children with CTM prophylaxis is
likely to protect them from LRTIs, probably including PCP. For
the HIV-infected child the possibly increased risk of diarrhoea
is outweighed by the benefits of protection against LRTI.
However, for HIV-uninfected infants this may not be the case,
and there is the additional public health risk that unnecessary
treatment in this much larger group of HIV-exposed children
will increase resistance to the drug.  We therefore recommend
that ideally all HIV-exposed children be tested at 6 weeks of
age, and only infected children be provided with CTM
prophylaxis.  Although the cost of a PCR test for HIV is
currently prohibitive in developing countries, in South Africa a
PCR test is now available for R150 in some laboratories.  It is
likely that for most developing countries the costs of tests will
become affordable.  An affordable PCR test at 6 weeks is an
attractive option because the cost will probably equate to the
financial and other consequences of increasing the prevalence
of resistance to CTM, one of the mainstays of antibiotic
treatment in developing countries.  Testing infants at 6 weeks
also provides the additional advantage of using this
information to inform mothers’ decisions on continuation or
cessation of breast-feeding.
Although our study had obvious shortcomings as it was not
a randomised controlled trial, it is the first study in Africa to
examine the effect of CTM prophylaxis on LRTI and diarrhoea
incidence in HIV-exposed children.  The results therefore
provide valuable information to inform policy on CTM
prophylaxis for all HIV-exposed infants in developing
countries.  A further limitation of our study is that children
presenting with LRTIs were not investigated for causal agents
and it can only be assumed from previous and current studies
in South African hospitals that a large burden of this disease is
PCP-related.16
The strength of the study is that morbidity data were
collected prospectively for a large number of infants (with
similar background profiles) who received similar management
in all aspects except with regard to CTM prophylaxis.  In
addition the control group was not a historical control as both
groups of infants were managed during the same time period.
The analysis controlling for several variables further
strengthens the inferences made.
A recent study in South Africa16 retrospectively examined
whether HIV-infected children presenting with pneumonia had
been exposed to CTM prophylaxis.  P. carinii was isolated less
frequently in children receiving CTM prophylaxis, and none of
the children with confirmed PCP who died had received CTM
prophylaxis. However, at least one-quarter of children in
whom PCP was diagnosed were receiving prophylaxis at the
time of their presentation.  This may suggest that CTM
prophylaxis is obviously not 100% effective and P. carinii
strains resistant to sulfa drugs may be emerging.17 There is also
the probability of non-adherence to treatment.  These findings
are similar to those reported here in our study.
We therefore recommend that developing countries continue
providing CTM prophylaxis to HIV-exposed infants.  However,
serious consideration should be given to developing affordable
tests for HIV and determining HIV status early so that those
infants who are HIV-negative are not unnecessarily exposed to
the unwanted side-effects of unnecessary treatment.
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